Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the incidence and severity of late Cytomegalovirus
(CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and
200 days and after 200 days post-transplant in patients treated with valganciclovir per
package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
versus valganciclovir per package insert guidelines for 100 days post-transplant with Cytogam
100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant.